LivaNova appoints Don Zurbay to board of directors

LONDON - Medical technology company LivaNova PLC (NASDAQ:LIVN), currently trading near its 52-week high with a market capitalization of $3.1 billion, announced Thursday the appointment of Donald Zurbay to its Board of Directors, effective immediately. Zurbay will serve on the company’s Audit and Compliance Committee.According to InvestingPro data, LivaNova has received positive attention from analysts, with six analysts recently revising their earnings estimates upward for the upcoming period.

Zurbay brings 30 years of experience in finance, accounting, and strategy to the board. He most recently served as President and Chief Executive Officer at Patterson Companies, Inc., a global healthcare company, where he previously held the position of Chief Financial Officer. Before joining Patterson, Zurbay spent nearly 13 years at St. Jude Medical in various leadership roles, ultimately serving as CFO.

"Over the course of 30 years, he has amassed expertise in finance, accounting, and strategy, much of which he honed while serving in leadership positions with global healthcare companies," said William Kozy, Chair of the Board, in a press release statement.

Currently, Zurbay also serves on the Board of Directors at Sight Sciences, Inc., where he chairs the Audit Committee and is a member of the Compensation Committee. His previous board appointments include Avedro, Inc. and Silk Road Medical, Inc.

Zurbay holds a bachelor’s degree in business accounting from the University of Minnesota. His earlier career includes positions at PricewaterhouseCoopers, The Valspar Corporation, and Deloitte & Touche.

With this appointment, the LivaNova Board now consists of 11 Directors.

LivaNova, headquartered in London, employs approximately 2,900 people and operates in more than 100 countries, focusing on medical technologies for select neurological and cardiac conditions.

In other recent news, LivaNova PLC reported impressive second-quarter results for 2025, with earnings per share (EPS) significantly exceeding expectations. The company achieved an EPS of $1.05, surpassing the forecasted $0.87 by 20.69%. Additionally, LivaNova’s revenue reached $353 million, outperforming the anticipated $332.21 million. In another development, Barclays raised its price target for LivaNova to $58 from $55 while maintaining an Equalweight rating. This adjustment reflects Barclays’ upward revision of sales projections by approximately 3% for 2025, aligning with management’s updated outlook. Furthermore, the firm increased its sales projections by about 9% on average per year for 2026 and beyond. These developments highlight the company’s robust financial performance and positive future outlook as assessed by analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.